These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35007145)

  • 41. Clinical Practice. Postmenopausal Osteoporosis.
    Black DM; Rosen CJ
    N Engl J Med; 2016 Jan; 374(3):254-62. PubMed ID: 26789873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fracture risk associated with chronic use of bisphosphonates: evidence today.
    Charopoulos I; Orme S; Giannoudis PV
    Expert Opin Drug Saf; 2011 Jan; 10(1):67-76. PubMed ID: 21121870
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of teriparatide in osteoporotic fracture patients.
    Collinge C; Favela J
    Injury; 2016 Jan; 47 Suppl 1():S36-8. PubMed ID: 26768289
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of Low Bone Density or Osteoporosis to Prevent Fracture.
    Ann Intern Med; 2017 Jun; 166(11):. PubMed ID: 28492833
    [No Abstract]   [Full Text] [Related]  

  • 45. Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment.
    Modi A; Tang J; Sen S; Díez-Pérez A
    Curr Med Res Opin; 2015 Apr; 31(4):767-77. PubMed ID: 25708648
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fracture risk estimation may facilitate the treatment gap in osteoporosis.
    Lems WF
    Ann Rheum Dis; 2015 Nov; 74(11):1943-5. PubMed ID: 26408569
    [No Abstract]   [Full Text] [Related]  

  • 47. Adverse effects of bisphosphonates: implications for osteoporosis management.
    Kennel KA; Drake MT
    Mayo Clin Proc; 2009 Jul; 84(7):632-7; quiz 638. PubMed ID: 19567717
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [New bone density conservation agents for osteoporosis under research and development: ED-71].
    Hagino H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():454-8. PubMed ID: 18161148
    [No Abstract]   [Full Text] [Related]  

  • 49. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).
    Black DM; Reid IR; Boonen S; Bucci-Rechtweg C; Cauley JA; Cosman F; Cummings SR; Hue TF; Lippuner K; Lakatos P; Leung PC; Man Z; Martinez RL; Tan M; Ruzycky ME; Su G; Eastell R
    J Bone Miner Res; 2012 Feb; 27(2):243-54. PubMed ID: 22161728
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Web Exclusive. Annals Video Summary - Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis.
    Ann Intern Med; 2023 Feb; 176(2):eM223320. PubMed ID: 36592473
    [No Abstract]   [Full Text] [Related]  

  • 51. Medication management after intramedullary nailing of atypical fractures.
    Feron JM; Cambon-Binder A
    Injury; 2017 Jun; 48 Suppl 1():S15-S17. PubMed ID: 28456365
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
    Nakamura T; Fukunaga M; Nakano T; Kishimoto H; Ito M; Hagino H; Sone T; Taguchi A; Tanaka S; Ohashi M; Ota Y; Shiraki M
    Osteoporos Int; 2017 Jan; 28(1):389-398. PubMed ID: 27631091
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Measurement of bone mineral density is unnecessary for monitoring of bisphosphonate treatment].
    Nishida A; Ito M
    Clin Calcium; 2011 Jan; 21(1):120-3. PubMed ID: 21187605
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
    Khan AA; Morrison A; Kendler DL; Rizzoli R; Hanley DA; Felsenberg D; McCauley LK; O'Ryan F; Reid IR; Ruggiero SL; Taguchi A; Tetradis S; Watts NB; Brandi ML; Peters E; Guise T; Eastell R; Cheung AM; Morin SN; Masri B; Cooper C; Morgan SL; Obermayer-Pietsch B; Langdahl BL; Dabagh RA; Davison KS; Sándor GK; Josse RG; Bhandari M; El Rabbany M; Pierroz DD; Sulimani R; Saunders DP; Brown JP; Compston J;
    J Clin Densitom; 2017; 20(1):8-24. PubMed ID: 27956123
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Innovations in the treatment of osteoporosis].
    Tsourdi E; Hofbauer LC
    Dtsch Med Wochenschr; 2011 Dec; 136(48):2458-60. PubMed ID: 22109575
    [No Abstract]   [Full Text] [Related]  

  • 56. Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
    Hochberg MC
    Curr Osteoporos Rep; 2008 Sep; 6(3):89-94. PubMed ID: 18752769
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia.
    Mohd-Tahir NA; Thomas P; Mohamed-Said MS; Makmor-Bakry M; Li SC
    Int J Rheum Dis; 2018 Mar; 21(3):647-655. PubMed ID: 29105349
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of the prescription of osteoporosis treatment after a major osteoporotic fracture.
    Bouvet A; Sabatier B; Savoldelli V; Caruba T; Pouchot J
    J Clin Rheumatol; 2014 Sep; 20(6):347-8. PubMed ID: 25160027
    [No Abstract]   [Full Text] [Related]  

  • 59. Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture.
    Ferrari S; Reginster JY; Brandi ML; Kanis JA; Devogelaer JP; Kaufman JM; Féron JM; Kurth A; Rizzoli R
    Arch Osteoporos; 2016 Dec; 11(1):37. PubMed ID: 27800591
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The denosumab dilemma: to be stopped after 5 years or to be continued in patients with osteoporosis?].
    Wolffenbuttel BHR; Abma EM; Appelman-Dijkstra NM
    Ned Tijdschr Geneeskd; 2018 May; 162():. PubMed ID: 30040306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.